Our Programs


We are leveraging our deep understanding of recent biological discoveries in endocrinology to build our clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class treatments for orphan endocrine diseases with significant unmet need. Livoletide (AZP-531) is an unacylated ghrelin analogue for the treatment of Prader-Willi syndrome and nevanimibe (ATR-101) is an ACAT1 inhibitor being investigated in two orphan adrenal disease; classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome (CS).


Millendo Pipeline